New drug combo shows promise for tough hodgkin lymphoma cases
NCT ID NCT05723055
First seen Jan 05, 2026 · Last updated Jun 13, 2026 · Updated 20 times
Summary
This study tests a combination of two drugs, nivolumab and axatilimab, in adults with classical Hodgkin lymphoma that has returned or not responded to prior treatments, including anti-PD-1 therapy. The main goal is to see if the combination shrinks tumors. Nine participants are enrolled in this early-phase trial to check effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.